AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...
based on an analysis of (1) the occurrence of polyps and of allergy, (2) the anatomy and histology of nasal polyps, (3) the inflammation in nasal polyps, (4) the occurrence of positive allergy tests ...
Always ask your healthcare provider before starting a new medication. Pregnancy ... water For chronic sinusitis that doesn't respond to medication or at-home treatments, your healthcare provider may ...
This includes $2 billion of new investment creating more than a ... trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that AstraZeneca and Amgen ...
Some nasal sprays contain oxymetazoline ... can examine the inside of the nose with a light and recommend further testing or treatment if needed. Blood tests may be necessary if a doctor suspects ...